Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Operating Leases (2023 - 2025)

China SXT Pharmaceuticals (SXTC) has 3 years of Operating Leases data on record, last reported at $176648.0 in Q1 2025.

  • For Q1 2025, Operating Leases fell 25.1% year-over-year to $176648.0; the TTM value through Mar 2025 reached $176648.0, down 25.1%, while the annual FY2025 figure was $176648.0, 25.1% down from the prior year.
  • Operating Leases reached $176648.0 in Q1 2025 per SXTC's latest filing, down from $235848.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $306050.0 in Q1 2023 and bottomed at $176648.0 in Q1 2025.
  • Average Operating Leases over 3 years is $239515.3, with a median of $235848.0 recorded in 2024.
  • Peak YoY movement for Operating Leases: dropped 22.94% in 2024, then dropped 25.1% in 2025.
  • A 3-year view of Operating Leases shows it stood at $306050.0 in 2023, then dropped by 22.94% to $235848.0 in 2024, then decreased by 25.1% to $176648.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $176648.0 in Q1 2025, $235848.0 in Q1 2024, and $306050.0 in Q1 2023.